ArticlePharmacoEconomics1996
French economic evaluations of influenza and influenza vaccination.
Article in PharmacoEconomics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interventions to increase influenza vaccination rates of those 60 years and older in the community.The Cochrane database of systematic reviews · 2018Pooled it
- Interventions to increase influenza vaccination rates of those 60 years and older in the community.The Cochrane database of systematic reviews · 2014Pooled it
- Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.BMC infectious diseases · 2017Trial
- Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group.PharmacoEconomics · 2000Trial
- Influenza epidemics observed in primary care from 1984 to 2017 in France: A decrease in epidemic size over time.Influenza and other respiratory viruses · 2019Article
- Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany--results of a database analysis from May 2010 to April 2012.BMC public health · 2015Article
- Economic burden of seasonal influenza B in France during winter 2010-2011.BMC public health · 2014Article
- Review
- Cost-benefit analysis of influenza vaccination in a public healthcare unit.Therapeutics and clinical risk management · 2006Article
- Antiviral agents for influenza: a comparison of cost-effectiveness data.PharmacoEconomics · 2005Review
- Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children.Clinical drug investigation · 2004Article
- A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.PharmacoEconomics · 2002Article
- Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.Drugs · 2002Review
- Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.Drugs & aging · 2000Review
- Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.PharmacoEconomics · 2000Article
- Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.Clinical pharmacokinetics · 1999Review
- Influenza. The role of burden-of-illness research.PharmacoEconomics · 1999Review
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cost-of-illness studies of influenza performed in France or the years 1985 and 1989 have shown that the major economic consideration in the respective sizes of indirect and direct costs. Depending on the point of view (from the perspective of National Health Insurance or the societal perspective) and the method used for measuring indirect costs, it was estimated that they could be between 1.5 and 9 times higher than direct costs. A cost-benefit study of influenza vaccination for the employed adult population showed that vaccination is a cost-saving strategy, although this was also contingent upon the problems associated with measuring indirect benefits as well as the effectiveness rate of vaccination in real conditions.
Indexed as
Identifiers
10160489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.